Selection of Optimal Adjuvant Chemotherapy Regimens for Early Breast Cancer and Adjuvant Targeted Therapy for HER2-Positive Breast Cancers: An American Society of Clinical Oncology Guideline Adaptation of the Cancer Care Ontario Clinical Practice Guideline Summary

Adjuvant chemotherapy improves disease-free survival (DFS) and overall survival (OS) independent of age, nodal status, and estrogen receptor (ER) status. However, those with triple-negative and human epidermal growth factor receptor 2 (HER2) –positive breast cancer seem to derive the greatest proportional benefit from systemic chemotherapy and biologic therapy. The potential benefits and risks need to be carefully weighed before a decision to administer chemotherapy is rendered; comorbidities and burden of disease need to be considered for selection of optimal regimens.

 Journal of Oncology Practice

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.